Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Aleve, Anaprox, Naprosyn, Flanax, Midol Extended Relief, Naproxen EC
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, fever, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, menstrual cramps, and other types of pain. It works by inhibiting the production of prostaglandins, which are chemicals that contribute to pain and inflammation.
For pain, fever, inflammation, and stiffness associated with various conditions like osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders.
Naproxen, like other NSAIDs, may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Naproxen is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.
Outcome:
Increased bleeding risk
Mechanism:
Naproxen can displace warfarin from protein binding sites, increasing its free concentration.
Outcome:
Increased bleeding risk
Mechanism:
Both SSRIs and NSAIDs can impair platelet function.
Outcome:
Reduced naproxen absorption
Mechanism:
Antacids can alter the pH of the stomach, affecting drug absorption.
Most likely new formulation: Long-acting topical patch (Year: 2026, 70% confidence)
Based on current usage trends and safety profile, naproxen is expected to maintain its current regulatory status with a 95% likelihood over the next 5 years.
Nonsteroidal anti-inflammatory drug (NSAID)
Propionic Acid Derivative